MWB raises target for Drägerwerk stock to EUR 130.00

Published on 10/01/2026 at 16:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half sales rose 7.70 percent to EUR 1.60 billion. Drägerwerk stock costs EUR 119.20 on October 1, 2026 versus EUR 120.80, minus 1.32 percent.

Architekturvisualisierung eines modernen Medizintechnik-Forschungsgebäudes mit Glasfassade — Drägerwerk AG & Co. KGaA modernes Forschungsgebäude Medizintechnik Glasfassade Architekturrender Unternehmensanlage DE0005550636, Illustration mit AI erstellt.

Drägerwerk stock was trading at EUR 119.20 at Lang & Schwarz on October 1, 2026, down 1.32 percent from the prior close of EUR 120.80. MWB Research raised its price target to EUR 130.00 on September 10, 2026, citing greater confidence in the medical technology group's margin development, according to wallstreetONLINE.

Margins support the higher target

Drägerwerk's first-half 2026 performance provides the operating basis for that target. Net sales grew 7.70 percent to EUR 1.60 billion, while EBIT rose from EUR 20 million in the prior-year period to EUR 64 million, according to Yahoo Finance. The resulting EBIT margin reached 4.00 percent, compared with 1.30 percent in the prior-year period.

The improvement was broad enough to affect both divisions. Safety technology delivered first-half EBIT of EUR 78 million, up from EUR 54 million, while medical technology reduced its EBIT loss to EUR 14.3 million from EUR 33.7 million, according to Yahoo Finance. That contrast matters because the stronger safety division is currently carrying profitability while the larger medical business recovers.

Guidance puts execution first

Management expects currency-adjusted net sales growth of 2.00 percent to 6.00 percent in fiscal 2026 and now guides to an EBIT margin of 6.00 percent to 8.00 percent, the earnings-call transcript reported on July 30, 2026. The outlook includes additional customs refunds, creating a comparison point for investors: the margin target is materially above the 4.00 percent achieved in the first half.

Drägerwerk also plans to discuss its longer-term path at an analyst and investor day on November 18, 2026. The company has stated an ambition to lift its EBIT margin by one percentage point per year and reach 10.00 percent by 2030, according to Yahoo Finance.

Third-quarter date is set

The next scheduled earnings release is October 29, 2026, when Drägerwerk is due to publish its third-quarter results. The calendar also lists an analyst and investor day for November 18, 2026, according to MarketScreener.

Stock stays below its yearly high

At EUR 119.20, the Lang & Schwarz price stood 4.94 percent below the 52-week high of EUR 125.40 and above the 52-week low of EUR 64.40 on October 1, 2026. Market capitalization was EUR 2.2 billion at the same date, giving the margin outlook and the October results a direct valuation context.

The further course of trading is shown by the continuously updated real-time quote of Drägerwerk stock.